BIOABioAge Labs, Inc.

1. Oct 2, 2026BioAge Labs, Inc. (the “Company”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (“DME”), and provided updates on the QUELL-DME Phase 2 trial design.Other event · Form 8-K
2. May 8, 2026BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
3. Mar 24, 2026BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025.Earnings release · press release
4. Jan 22, 2026On January 21, 2026, BioAge Labs, Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters named therein (the “Underwriters”), pursuant to …Material agreement entered · Form 8-K
5. Jan 20, 2026Planned proof-of-concept clinical trial in DME On January 20, 2026, the Company announced indication expansion for oral NLRP3 inhibitor BGE-102. • Growing preclinical and clinical evidence points to central role of the inflammasome in multiple retinal diseases where inflammation is a key feature, including diabetic …Regulation FD disclosure · Form 8-K
6. Jan 12, 2026Phase 1 Data for BGE-102 On January 12, 2026, the Company announced additional positive interim Phase 1 data for BGE-102, a novel brain-penetrant NLRP3 inhibitor, demonstrating potential for best-in-class hsCRP reduction in participants with elevated cardiovascular risk. • First BGE-102 multiple ascending dose (“MAD”) …Regulation FD disclosure · Form 8-K
7. Dec 4, 2025Phase 1 Data for BGE-102 On December 4, 2025, the Company announced positive interim data from its ongoing Phase 1 single ascending dose (SAD) / multiple ascending dose (MAD) clinical trial evaluating BGE-102 a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor being developed …Regulation FD disclosure · Form 8-K
8. Nov 6, 2025BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.